Drug Discov Ther. 2014;8(6):249-254. (DOI: 10.5582/ddt.2014.01050)
In vitro and in vivo anti-MRSA activities of nosokomycins.
Uchida R, Hanaki H, Matsui H, Hamamoto H, Sekimizu K, Iwatsuki M, Kim YP, Tomoda H
The anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of nosokomycins A to D discovered in the silkworm-MRSA infection screening was investigated. The minimum inhibitory concentration (MIC) values of nosokomycins for authentic MRSA and S. aureus strains were calculated to be 0.06 to 2.0 μg/mL. They also showed potent inhibitory activity against 54 clinically isolated MRSA strains. Furthermore, nosokomycin A proved effective in the mouse-MRSA infection model.
KEYWORDS: Nosokomycins, silkworm infection assay, anti-MRSA antibiotic, Streptomyces cyslabdanicus K04-0144, therapeutic efficacy